Enhertu

News

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo

News

Ambrx tries another IPO as it chases down HER2 rivals

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, it

News

Enhertu cleared for NHS use via Cancer Drugs Fund

NICE has recommended the use of AstraZeneca and Daiichi Sankyo's Enhertu in draft guidance, the first time the drug has been commissioned in any European country.

News

AZ/Daiichi Sankyo's Enhertu gets second US cancer indication

AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab).

News

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antib

Views & Analysis

Antibody-drug conjugates on the march

One of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal with Japan’s Daiichi Sankyo, focused on just one breast cancer drug.

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Ambrx tries another IPO as it chases down HER2 rivals

Enhertu cleared for NHS use via Cancer Drugs Fund

AZ/Daiichi Sankyo's Enhertu gets second US cancer indication

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Antibody-drug conjugates on the march

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Enhertu

Editor's Picks